Innovations In Clinical Neuroscience

MAR-APR 2017

A peer-reviewed, evidence-based journal for clinicians in the field of neuroscience

Issue link: http://innovationscns.epubxp.com/i/822795

Contents of this Issue

Navigation

Page 36 of 45

Innovations in CLINICAL NEUROSCIENCE [ V O L U M E 1 4 , N U M B E R 3 – 4 , M A R C H – A P R I L 2 0 1 7 ] 37 31. Funato H. Orexin and metabolism. In: Sakurai T, Pandi-Perumal SR, Monti JM (eds). Orexin and Sleep: Molecular, Functional and Clinical Aspects. New York: Springer; 2015:363–390. 32. Kalsbeek A, Yi CX, la Fleur SE, et al. Suprachiasmatic nucleus and autonomic nervous system influences on awakening from sleep. Int Rev Neurobiol. 2010;93:91–107. 33. Tsuneki H, Wada T, Sasaoka T. Role of orexin in the central regulation of glucose and energy homeostasis. Endocr J. 2012;59:365–374. 34. Shiuchi T, Haque MS, Okamoto S, et al. Hypothalamic orexin stimulates feeding-associated glucose utilization in skeletal muscle via sympathetic nervous system. Cell Metab. 2009;10:466–480. doi: 10.1016/j.cmet.2009.09.013. 35. Perez-Leighton CE, Billington CJ, Kotz CM. Orexin modulation of adipose tissue. Biochim Biophys Acta. 2014;1842:440–445. 36. Tsuneki H, Tokai E, Nakamura Y, et al. Hypothalamic orexin prevents hepatic insulin resistance via daily bidirectional regulation of autonomic nervous system in mice. Diabetes. 2015;64:459–470. doi: 10.2337/db14- 0695. 37. Haynes AC, Chapman H, Taylor C, et al. Anorectic, thermogenic and anti- obesity activity of a selective orexin-1 receptor antagonist in ob/ob mice. Regul Pept. 2002;104:153–159. 38. Shirasaka T, Nakazato M, Matsukura S, et al. Sympathetic and cardiovascular actions of orexins in conscious rats. Am J Physiol. 1999;277:R1780–1785. 39. Li A, Hindmarch CC, Nattie EE, Paton JF. Antagonism of orexin receptors significantly lowers blood pressure in spontaneously hypertensive rats. J Physiol. 2013;591:4237–4248. doi: 10.1113/jphysiol.2013.256271. 40. Kuru M, Ueta Y, Serino R, et al. Centrally administered orexin/hypocretin activates HPA axis in rats. Neuroreport. 2000;11:1977– 1980. 41. Lu J, Bjorkum AA, Xu M, et al. Selective activation of the extended ventrolateral preoptic nucleus during rapid eye movement sleep. J Neurosci. 2002;22:4568–4576. 42. Marcus JN, Aschkenasi CJ, Lee CE, et al. Differential expression of orexin receptors 1 and 2 in the rat brain. J Comp Neurol. 2001;435:6–25. 43. Malendowicz LK, Hochol A, Ziolkowska A, et al. Prolonged orexin administration stimulates steroid- hormone secretion, acting directly on the rat adrenal gland. Int J Mol Med. 2001;7:401–404. 44. Spinazzi R, Rucinski M, Neri G, et al. Preproorexin and orexin receptors are expressed in cortisol-secreting adrenocortical adenomas, and orexins stimulate in vitro cortisol secretion and growth of tumor cells. J Clin Endocrinol Metab. 2005;90:3544– 3549. 45. Kok SW, Roelfsema F, Overeem S, et al. Dynamics of the pituitary-adrenal ensemble in hypocretin-deficient narcoleptic humans: blunted basal adrenocorticotropin release and evidence for normal time-keeping by the master pacemaker. J Clin Endocrinol Metab. 2002;87:5085– 5091. 46. Nakagawa M, Terashima T, D'yachkova Y, et al. Glucocorticoid-induced granulocytosis: contribution of marrow release and demargination of intravascular granulocytes. Circulation. 1998;98:2307–2313. 47. Benschop RJ, Rodriguez-Feuerhahn M, Schedlowski M. Catecholamine- induced leukocytosis: early observations, current research, and future directions. Brain Behav Immun. 1996;10:77–91. 48. Patel AX, Miller SR, Nathan PJ, et al. Neuroendocrine and sympathetic responses to an orexin receptor antagonist, SB-649868, and alprazolam following insulin-induced hypoglycemia in humans. Psychopharmacology (Berl). 2014;231:3817–3828. doi: 10.1007/s00213-014-3520-7

Articles in this issue

Archives of this issue

view archives of Innovations In Clinical Neuroscience - MAR-APR 2017